Key Drivers
- Gross Margin
- Debt Surge
- Weak Coverage
AIAI Summary
HROW is shifting from a “story stock” to a commercial scaling case where the real investment test is whether strong revenue momentum can translate into durable operating leverage fast enough to offset rising debt and thin interest coverage, making execution on margin expansion the key catalyst and the main risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Gross Margin
- •Debt Surge
- •Weak Coverage
HROW still has solid gross margins and near-term liquidity, but sharply weaker quarterly profitability, thin interest coverage, and extreme leverage make the stock high risk despite elevated sales-based valuation.
Price Behavior
Key Price Behavior Insights:
- •Downtrend cooling
- •Higher lows forming
- •Resistance overhead
HROW remains in a last month downtrend, but the selloff appears to have stabilized near $37.46 with a short-term recovery underway; watch for a hold above $39 and a breakout above $40.70 and then $41.9-$42.8 to confirm momentum.
Fell from $46.65 to $40.03, then bounced from a late-July floor near $37.46
Sentiment & News
Key News Insights:
- •Revenue Surge
- •Pipeline Validation
- •Loss Wider
Harrow posted strong revenue growth and advanced its eye-care portfolio with the TYRVAYA® rights acquisition and supportive BYOOVIZ/IHEEZO data, but the latest quarter was weighed down by a wider-than-expected loss.
The news is mildly positive for long-term growth as commercial momentum and asset expansion improve the strategic outlook, though near-term profitability remains under pressure
Similar Companies in Healthcare
Other companies in the same sector with AI ratings